| Barchart Demo Center |
$2.64
+0.62 (+30.69%)
as of May 31, 2024
as of May 31, 2024
| Profile | |
|---|---|
| Ticker Symbol | CYCC |
| Exchange | NASDAQ |
| Contact Information |
200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS, NJ USA P: 908-517-7330 |
| CEO/President | Spiro Rombotis |
| Earnings at a Glance | ||||
|---|---|---|---|---|
| Earnings | 03/31/24 -2.27 |
12/31/23 -5.96 |
09/30/23 -7.20 |
06/30/23 -6.60 |
| Price Earnings Ratio | N/A | |||
| EPS Growth | 76.37 | |||
| Most Recent Earnings ($) | -2.27 | |||
| Annual EPS ($) | -22.44 | |||
| Business Summary | |
|---|---|
| CYCLACEL is a biopharmaceutical company dedicated to the discovery development and commercialization of novel mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine a cell cycle modulating nucleoside analog is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine) a CDK inhibitor is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. | |
| Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Biomedical |